A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Saved in:
| Title: | A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. |
|---|---|
| Authors: | Kipps TJ; a Department of Hematology-Oncology , UCSD School of Medicine , San Diego , CA , USA., Eradat H; b Division of Hematology-Oncology, David Geffen School of Medicine at UCLA , Los Angeles , CA , USA., Grosicki S; c Department of Hematology , Community Hospitals , Chorzow , Poland., Catalano J; d Frankston Hospital and Monash University , Frankston , Australia., Cosolo W; e John Fawkner Cancer Trial Centre , Coburg , Australia., Dyagil IS; f Department of Hematology , National Research Center for Radiation Medicine of National Medical Academy of Sciences of Ukraine , Kyiv , Ukraine., Yalamanchili S; g Genentech, Inc. , South San Francisco , CA , USA., Chai A; g Genentech, Inc. , South San Francisco , CA , USA., Sahasranaman S; g Genentech, Inc. , South San Francisco , CA , USA., Punnoose E; g Genentech, Inc. , South San Francisco , CA , USA., Hurst D; g Genentech, Inc. , South San Francisco , CA , USA., Pylypenko H; h Department of Hematology , Cherkassy Regional Oncological Center , Cherkassy , Ukraine. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (10), pp. 2826-33. Date of Electronic Publication: 2015 May 12. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
